関連する実験動画
Updated: Jun 28, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
非活性酵素構成を標的とする: PTP1B 阻害剤の新種としてアリル二酸化酸誘導体
Sijiu Liu1, Li-Fan Zeng, Li Wu
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA.
Journal of the American Chemical Society
|November 18, 2008
まとめ
研究者らは,新型アリルディケトアシドをタンパク質チロシンフォスファタゼ1B (PTP1B) の強力な阻害剤として特定した. これらの細胞透過性化合物はインスリンシグナル伝達を強化し,糖尿病や肥満の治療に新たな治療的可能性を秘めています.
科学分野:
- バイオケミストリー バイオケミストリー
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- タンパク質チロシンファスファタゼ1B (PTP1B) は,代謝疾患やがんの主要な治療標的である.
- 細胞に浸透するPTP阻害剤の開発は,現在の充電された薬理学の限界のために困難です.
研究 の 目的:
- 細胞の浸透性と薬理学的特性を改善した新しいPTP1B阻害剤を特定する.
- PTP1Bを標的とする潜在的な剤としてアリルディケト酸およびその二次派生物を調査する.
主な方法:
- アリルディケト酸をフォスフォチロジン (pTyr) 代替物として識別する.
- 中性アミドと結合したアリルディケト酸二酸化物の合成と評価.
- 阻害メカニズムを決定するための運動学的研究.
- 結合モードを明らかにするためのX線結晶学.
- 肝腫細胞における細胞透過性とインスリンシグナル伝達強化の評価.
主要な成果:
- アリルディケト酸およびその二次派生体は,強力なPTP1B抑制活性を示しています.
- これらの化合物は,PTP1B.の非競争的阻害剤として作用する.
- 結晶構造は,不活性なPTP1B形状における阻害剤の明確な結合モードを明らかにします.
- ディメリックアリルディケトアシドは細胞に浸透し,インスリンシグナル伝達を強化します.
結論:
- アリルディケトアシドは,PTP1B阻害剤の新しいクラスを表しています.
- PTP1Bの非活性構成をターゲットにすると,より優れた薬理学的プロファイルを持つ阻害剤が得られます.
- これらの発見は,糖尿病と肥満のための新しい治療法を開発するための有望な戦略を提供します.
関連する概念動画
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...